Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs TransMedics Group Inc (TMDX) Price & Performance

Abeona Therapeutics IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs TransMedics Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 7.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

ABEOTMDX
Market Cap
$421.19M$3.10B
Sector
HealthTechnology
52-Week High
$7.45$150.42
52-Week Low
$4.17$61.99
Enterprise Value
$276.10M$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX